SHPG News and Press, Shire plc

Among many non-alcoholic steatohepatitis (NASH) drug innovators, Madrigal Pharmaceuticals is poised to deliver the first medicine to the market sometime next year. By Q4 this year, the company is anticipated to report data for the Phase 3 (MAESTRO-NASH) trial. Despite strong funda...

Homology Medicines (FIXX) announces the promotion of Tim Kelly to chief operating officer from previously held role of the company's chief technical operating officer.The change in effective immediately.Prior to joining Homology Medicines, Kelly has held leadership positions at Shire (SH...

Vallon Pharmaceuticals has filed to raise $15 million in an IPO. The firm is developing reformulated treatments for ADHD and narcolepsy. VALL is a tiny and thinly capitalized firm. While I wish it well, I'll pass on the IPO. For further details see: IPO Update: Vallon Ph...

Pharming Group N.V. has filed to offer an estimated $10.9 million in Registered Holder shares in a U.S. offering. The firm is commercializing a treatment for hereditary angioedema and developing a treatment for pneumonia brought on by the Covid-19 virus. The firm is generating rev...

Vallon Pharmaceuticals has filed to raise $17 million in a U.S. IPO. The firm is developing reformulated drug treatment candidates for ADHD and narcolepsy. VALL is related to investor Arcturus Therapeutics, from whom it obtained its core technologies. For further details see...

NLS Pharmaceutics has filed to raise $20 million in a U.S. IPO. The firm is advancing treatments for narcolepsy and ADHD. NLSP is thinly capitalized and has made no apparent progress on beginning trials for its lead candidate, so I'll pass on the IPO. For further details see...

Introduction In March, I wrote an article about Genfit (NASDAQ: GNFT ) and the potential of its lead drug candidate Elafibranor in NASH. In my analysis, I underlined the huge upward potential but also underpinned the binary characteristic of the investment case. My recommendation was to ...

Quick Take NLS Pharmaceutics ( NLSP ) has filed to raise $40.25 million in an IPO of its common stock, according to an F-1 registration statement . The company is advancing a pipeline of drug candidates for the treatment of various central nervous system disorders. NLSP expects to begin...

After updating investors earlier this week on the timeline for filing a new drug application for its lead drug candidate, maralixibat, in Alagille syndrome (ALGS), Mirum Pharmaceuticals  (NASDAQ:MIRM) saw its shares rally 44.1% on Wednesday. Mirum is a relatively new company ded...

As the US Department of Health and Human Services notes, Alzheimer’s disease (AD) is a degenerative brain disorder that results in cognitive decline and basic thinking skills which slowly gets worse over time. According to a 2019 Alzheimer’s disease facts and figures re...